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The aetiology of idiopathic Parkinson’s disease
D B Ramsden, R B Parsons, S L Ho, R H Waring
Abstract
Agents potentially involved in the aeti-
ology of idiopathic Parkinson’s disease are
discussed. These include factors regulat-
ing dopaminergic neurogenesis (Nurr 1,
Ptx-3, and Lmx1b) and related proteins,
together with genes involved in familial
Parkinson’s disease (á synuclein, parkin,
and ubiquitin carboxy terminal hydroxy-
lase L1), and endogenous and environ-
mental agents.
(J Clin Pathol:Mol Pathol 2001;54:369–380)
Keywords: Parkinson’s disease; environmental agents;
transcription factors; á synuclein; parkin; ubiquitin car-
boxy terminal hydroxylase L1
Idiopathic Parkinson’s disease appears not to
be a single entity but rather a spectrum of con-
ditions resulting from the death of the
pigmented dopaminergic neurones of the sub-
stantia nigra, pars compacta, which ultimately
leads to the one single, fatal endpoint. As such,
this spectrum is unlikely to have a single cause.
Despite an intense research eVort over many
years, these causes still await elucidation. Vari-
ous factors contribute to the diYculties in the
search. Some obvious ones are the long period
between the initiation of the disease process
and the manifestation of clinical symptoms, the
lack of any distinctive blood biochemistry with
which to trace the disease process, and the
inadequacy of current animal models. Quite
when idiopathic Parkinson’s disease begins is
uncertain. Based on the premise that clinical
symptoms appear when approximately 50% of
pigmented dopaminergic neurones are dead
and the surviving ones can supply the striatum
with only about 20–30% of its dopamine
demand, mathematical models of neuronal
death rates suggest that there may be as small a
gap as three years or as large a one as 20. How-
ever, beyond the strictly mathematical, clinical
case histories of twins suggest the presence of a
“parkinsonian” personality that, in hindsight,
was present in very early life. Whether such a
personality exists and, if so, whether it implies
the presence of the disease process so early in
life remain obscure. Nevertheless, the concept
that early life events might be of crucial
importance has been moved from the realms of
fancy with the recognition of the role of specific
transcription factors in brain development,
particularly the proteins Nurr 1 (and its related
subfamily members), Lmx1b, and Ptx-3.
These are transcription factors that are in-
volved in determining neurogenesis in the basal
ganglia. It has been hypothesised that imma-
ture neurones die by apoptosis because of neu-
rotrophic factor deprivation, as a result of fail-
ing to make adequate contacts in their target
sites, whereas mature neurones die because of
toxic insult. However, the quality of contact
and/or degree of neurotrophic support in early
life may be of importance in determining the
length of survival. In addition, these proteins
are expressed throughout life in the basal gan-
glia, which suggests that they have roles in
maintaining the continuing health of specific
neurones and makes them worthy of considera-
tion in terms of the aetiology of idiopathic Par-
kinson’s disease. These factors often have mul-
tiple names, which sometimes relate to the
diVerent species that research groups were
investigating, or simply to diVerent phenomena
that were being considered at the time. For the
sake of simplicity only one name will be used
here in the main body of the text, but alterna-
tive names are listed.
Factors involved in dopaminergic
neurogenesis
NUR RELATED FACTOR 1 (NURR 1) (ALSO KNOWN
AS NOT, RNR-1, AND HZF-3)
Nurr 1 is a member of the superfamily of “zinc
finger” transcription factors.1 Over 90 mem-
bers of the superfamily have been described.
Included among these are the hormone recep-
tors for triiodothyronine, oestradiol, cortisol,
aldosterone, vitamin D, all trans retinoic acid,
and 9-cis retinoic acid. Increasingly, molecules
that at one time were thought of as unlikely
candidate ligands for these transcription fac-
tors are now being recognised as such. In the
past few years, it has been established that bile
acids modulate gene transcription via farnesyl
receptors.2 Nevertheless, many members of the
superfamily have no known ligands—so called
“orphan”receptors (reviewed by Enmark and
Gustafsson3)—but despite this, the functions of
these receptors are becoming recognised. Most
recently, cholesterol entry and egress from cells
has been shown to be regulated via such
orphans.4 5 Also among this class of receptors is
Nurr 1.
Nurr 1 was first recognised as a transcription
factor that was primarily expressed in the
brain6 and the regenerating liver7 (some details
of the gene, cDNA, and protein are given in
table 1, together with those for Ptx-3 and
Lmx1b). Its close structural relation to Nur 77
led to its identification in stimulated T cells,
where it functions as an intermediate early
response gene, with stimulation causing a rapid
increase in mRNA without the need for de
novo protein synthesis.1 Inhibition of Nurr 1
binding to its response element led to ineY-
cient clonal deletion of self reactive T cells.34 It
also functions as an intermediate early gene in
the central nervous system (CNS), being
rapidly induced in response to focal injury,35
but an appreciation of its crucial importance in
brain development came later, after it was




























shown to be expressed strongly in the midbrain
region.16 36 In mice in which the expression of
Nurr 1 is prevented (−/− knockout), there is a
failure of development of midbrain dopaminer-
gic neurones, with a 98% reduction in striatal
dopamine and a 30% reduction in noradren-
aline.37 38 In the olfactory bulb, another area
that is important in idiopathic Parkinson’s dis-
ease (70% of patients with idiopathic Parkin-
son’s disease have olfactory bulb dysfunction,
and anosia may precede other signs of the dis-
ease), Nurr 1 (−/−) mice have a 60% reduction
in dopamine,37 although claims concerning the
details of Nurr 1 expression in the olfactory
bulb are conflicting.39 40 The importance of
Nurr 1 for dopaminergic neurones can be seen
in relation to tyrosine hydroxylase expression,
as shown by the degree of coexpression of the
two proteins in the adult mouse brain, namely:
substantia nigra (96%), ventral tegmental area
(95%), retrorubral field (91%), olfactory bulb
(85%), linear nucleus raphe (91%), central
grey (61%), paraventricular and periventricu-
lar hypothalamic nucleus (few), and arcuate
nucleus and zona incerta (0%).41 In the
absence of the growth of the nigral dopaminer-
gic neurones, the animals fail to thrive and die
shortly after birth. In contrast, heterozygous
animals (+/− Nurr 1 mice) are apparently
healthy but have reduced midbrain dopamine
values.37 In humans, a similar role for Nurr 1 in
dopaminergic neurogenesis is assumed.
Nurr 1 is not only expressed throughout life
in midbrain neurones, but also in other regions
unconnected with idiopathic Parkinson’s dis-
ease,42 suggesting that it plays an important role
in maintaining the continuing health of all
these cells. Exactly what the role of Nurr 1 is in
the development of idiopathic Parkinson’s dis-
ease remains uncertain. Treatment of Nurr 1
deficient (−/+) animals with MPTP (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) showed
that they were more susceptible to the eVects of
the neurotoxin than normal (+/+) mice.43 The
identification of such a factor, which acts from
early fetal life onwards, raises the possibility
that diVerences in the amount of expression
and/or the timing of the onset of expression in
the fetal period may be important in predispos-
ing these cells to an earlier that normal death
and, thence, the development of idiopathic
Parkinson’s disease. Other intriguing possibili-
ties that surround Nurr 1 centre on its potential
ligand binding ability and its immune respon-
siveness. As mentioned earlier, Nurr 1 is
classed as an orphan receptor. It may act as a
transcription factor without an endogenous
natural ligand,44 either binding as a monomer
to its response element, or as a dimer.45
However, this does not of necessity rule out the
possibility that it can bind ligands, and binding
of any such ligand may alter its function
beneficially or deleteriously for the health of
the cell. Until developments in molecular biol-
ogy led to a re-evaluation of the evidence in the
past decade, idiopathic Parkinson’s disease was
thought to result exclusively from non-genetic
causes. However, it is now generally accepted
that genetics play a part. Nevertheless, as will
be reviewed later, environmental causes are still
thought to be of great importance. Any ability
of Nurr 1 either to bind endogenous or
exogenous ligands or to change in concentra-
tion in response to exposure to viruses or other
noxious stimuli oVers a portal to see how the
health of these cells might be uniquely
adversely aVected by environmental factors.
Furthermore, not only does Nurr 1 oVer the
possibility of theoretical insights, but also that
of practical exploration of dopaminergic neu-
ronal cell biology and replacement tissue for
implantation. In the past it was possible to cul-
ture neuronal cells, but these cultures were
highly heterogeneous mixtures of cells, making
culture to culture comparisons extremely diY-
cult. However, a culture system has been
described that overcomes this problem. This
involves three steps, namely: (1) the transfec-
tion of neuronal stem cells from mouse
cerebellum with a Nurr 1 expression plasmid
so that they overexpress Nurr 1; (2) the propa-
gation of the cells in the presence of basic
fibroblast growth factor; and (3) co-culture of
the cells in the presence of type 1 astrocytes to
supply other growth factors. The protocol leads
to the development of a dopaminergic pheno-
type in approximately 80% of the resultant
neurones.46 Such cultures should provide a
model in vitro system to enable a detailed
exploration of the physiology of these unique
cells. Further advances in cell culture tech-
niques, such as that described by Kawasaki et
al, which allow a slightly simpler method of
inducing a dopaminergic phenotype from a
modified embryonic stem cell line, will also
greatly aid this exploration.47 However, the
close structural relation of Nurr 1 to other
Table 1 Transcription factors involved in dopaminergic neurogenesis
Nurr 1
+ Member of “zinc finger” superfamily of receptors; its subfamily includes nerve growth factor
inducible B (NGFI-B) and neurone derived orphan receptor 1 (NOR-1)8
+ Human gene on 2q22–23; eight exons, spanning 8 kb. Murine, rat, and human genes have
similar structures9–12
+ Full length mRNA has 3427 bases, 1794 are translated; the protein has 598 amino acids (66
kDa)1 6; splice variants exist—for example, Nurr 2—a novel cryptic exon located upstream in
the Nurr 1 promoter region—and alternative splicing at exons 1, 2, and 613
+ Potential regulatory region contains consensus binding sites for nuclear factor êB (NF-êB),
cAMP response element binding protein (CREB), and Sp19 11 14
+ In the central nervous system (CNS) Nurr 1 expression occurs in the postmitotic late
diVerential phase of dopaminergic precursor neuronal development,15 16 detectable from rat
embryonic day 10.517
+ Nurr 1 response elements: a single half site (AAAGGTCA) binds Nurr 1 as monomer; this is
the same sequence as the NGFI-B response element7 8; a direct repeat (DR5)
(AGGTCANNNAAAGGTCA) binds Nurr 1/RXR as a heterodimer, Nurr 1 homodimers,
and the Nurr 1/NGFI-B heterodimer18–20
+ Nurr 1 response elements are found in tyrosine hydroxylase (AAAGGTCA),21 the dopamine
transporter,22 and other molecules such as proopiomelanocortin23
Ptx-3
+ Structurally related to pentaxins—for example, C reactive protein and serum amyloid P;
subfamily includes Ptx-1 and Ptx-2, and homeobox proteins such as Otx-1 and Otx-224 25
+ Human gene on chromosome 10.q25. has three exons26
+ cDNA has 1861 bp; protein has 381 amino acids25; Ptx-3 is also a secreted, acute phase
protein
+ mRNA induced in endothelial, hepatic, and fibroblastic cells by interleukin 1â (IL-1â) and
tumour necrosis factor á, but not by IL-6 and interferon ã; raised serum concentrations after
bacterial lipopolysaccharide injection25 27 28
+ Expression is restricted in the CNS29
+ The Ptx-3 response element is GGCTTT
+ There is a Ptx-3 response element in the tyrosine hydroxylase gene30
+ Mutations are associated with autosomal dominant cataracts26
Lmx1b
+ This transcription factor is related to members of the LIM family of homeobox proteins31
+ The human gene is on 9q34 and has eight exons32
+ Genetic mutations are associated with nail-patella syndrome33
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members of its subfamily suggests that it
should not be considered in isolation.
NERVE GROWTH FACTOR INDUCIBLE B (NGFI-B)
(ALSO KNOWN AS NUR 77/TR3/NAK1/N10/ST59/TIS)
AND NEURONE DERIVED ORPHAN RECEPTOR 1
(NOR-1) (ALSO KNOWN AS MINOR/TEC/CHN/NOR2)
Nurr 1, NGFI-B, and NOR-1 form a subfamily
within the “zinc finger” nuclear receptor
superfamily. Of the three, NGFI-B was the first
to be characterised. Like Nurr-1, NGFI-B and
NOR-1 play important roles in brain develop-
ment, and both are expressed in tissues outside
the CNS. The regional expression of NGBI-B
and NOR-1 within the CNS is diVerent from
that of Nurr 1, with that of NGFI-B being
wider, but the three do overlap, suggesting
selective roles for these transcription factors in
the regulation of motor function.48 49 Table 2
summarises the expression of the three sub-
family members in the CNS. Of possible
relevance to idiopathic Parkinson’s disease are
the facts that: (1) both NGFI-B and NOR-1
are expressed in the caudate/putamen, the tar-
get site for dopaminergic neurones from the
substantia nigra, but are not expressed in the
substantia nigra itself; and (2) NGFI-B,
NOR-1, and Nurr 1 are involved in the regula-
tion of dopamineric neurone formation in the
olfactory bulb, where NGFI-B is strongly
expressed in the glomerular and granule cell
layers.51
Human NGFI-B cDNA is 2498 bp in
length, with an open reading frame of 1794
base pairs, which encodes a protein of 598
amino acids and a predicted molecular mass of
64 kDa.52 53 The NGFI-B structural gene is
encoded on human chromosome 12q13.1,54
and the gene for NOR-1 is located on human
chromosome 9q22, spans some 35 kb, and has
eight exons.55 The NOR-1 gene gives rise to
two transcripts, which when translated result in
a protein containing 626 amino acids, with an
approximate molecular weight of 68 kDa. All
three receptors bind to a common response
element—AAAAGGTCA—as monomers.56
Nurr 1 and NGFI-B bind to AGGTCA repeats
as heterodimers with RXR isoforms,17 as
homodimers,57 and as a heterodimer with each
other.58 NOR-1 is unusual in that it does not
heterodimerise with RXR. x Ray crystallogra-
phy has shown that, when NGFI-B binds as a
monomer, the DNA binding domain of the
receptor not only interacts with the core
section of the response element (AGGTCA) in
the major groove, but also with the AAA exten-
sion via the minor groove.59
Like Nurr 1, NGFI-B and NOR-1 are inter-
mediate early genes. NGFI-B mRNA in brain
was induced rapidly and transiently by growth
stimulating agents,53 60 and in hippocampal
neurones in response to NMDA and mus-
carinic receptor stimulation.61 Both NGFI-B
and NOR-1 are expressed in the fetal brain and
are important signals in mitogenesis62 and
apoptosis pathways in tissues outside the
CNS.63 64
The role of these receptors in apoptotic sig-
nalling is complex. Both NGFI-B and NOR-1
generally are regarded as proapoptotic factors
in tissue outside the CNS.65 66 This appears to
be true for NGFI-B in the adult human CNS
too, with high amounts of the receptor being
detectable in the brains of patients with
Alzheimer’s disease.67. However, as indicated
above, both NGFI-B and NOR-1 are constitu-
tively expressed in some regions of the brain in
adult life where high rates of apoptotic neural
death are not occurring, so obviously they have
other functions, and in a model system where
overexpression of NGFI-B was induced, it
inhibited ceramide induced apoptosis but not
the Fas–Fas ligand pathway.68 Despite these
somewhat contradictory strands of evidence,
an understanding of the role of NGFI-B in
apoptosis and gene transcription is beginning
to emerge. An essential step in the initiation of
apoptosis is the release of cytochrome c from
mitochondria, which then activates the caspase
cascade.69 After exposure of the prostate cancer
cell line LNCaP to 6-[3-(1-adamantyl)-4-
hydroxyphenyl]-3-chloro-2-naphthalene car-
boxylic acid and other proapoptotic agents,
human NGFI-B was induced and the protein
was shown to move from the nucleus to the
mitochondrion to trigger cytochrome c release.
Therefore, in its role in apoptosis, human
NGFI-B is not required to initiate gene
transcription. Signals directing movement out
of the nucleus were contained in both the
N-terminus and C-terminus of the molecule.
Apoptosis was inhibited by antisense human
NGFI-B mRNA. In contrast, epidermal
growth factor (EGF)—a non-apoptotic
stimulus—also induced human NGFI-B
mRNA, but the protein produced stayed within
the nucleus and was capable of initiating gene
transcription.70 Therefore, it seems that the
contrasting actions of human NGFI-B are
modulated by its intracellular localisation,
which in turn is dependent upon the nature of
the signal to which the cell is exposed.
Export of human NGFI-B from the nucleus
is also a means of modulating gene transcrip-
tion via interaction with the retinoid signalling
system. After nerve growth factor induced
phosphorylation of NGFI-B serine residue
105, the NGFI-B–RXR complex leaves the
nucleus, reducing the availability of RXR for
heterodimerisation with RAR, which thus
reduces the transcriptional activity of the
RAR–RAR complex.71 Export of the RXR–
Table 2 Regional expression of Nurr 1,NGFI–B, and
NOR–1 mRNA in rat and mouse brain12 18 48 50
Area of brain
Nurr 1 NGFI–B NOR–1
A B A B A B
Neocortex ++ ++ +
Caudate putamen – ++ ++
Hippocampus ++ ++ ++
Olfactory bulb + ++ ++
Ventral tegmental
area ++ – –
Substantia nigra ++ – –
Subiculum ++ ++ ++
Locus coeruleus – – –
Cerebellum ++ ++ ++
Spinal cord – – –
A, early, neonatal life; B, later life.
++, strong expression; +, moderate expression; –, weak or no
expression.
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NGFI-B complex from the nucleus has also
been suggested as the mechanism whereby
retinoids inhibit the activation induced apopto-
sis of immature thymocytes. It was suggested
that this occurred because of the reduced abil-
ity of NGFI-B to initiate gene transcription,72
but it may be the result of the inability of the
RXR–NGFI-B heterodimer to interact with
the mitochondrion, in contrast to NGFI-B
alone.
The recent work on the role of NGFI-B in
apoptosis has been carried out largely in
non-CNS cells, and whether the same actions
and mechanisms apply in the CNS remains to
be seen. However, NGFI-B is inducible in the
dopaminergic target areas in the striatum in
response to burst stimulation of the medial
forebrain bundle,73 and both NGFI-B and
NOR-1 are inducible in response to therapeu-
tic drugs (halopyridol)74 and substances of
abuse (cocaine and morphine).75 The induc-
tion of NGFI-B and NOR-1 was suggested as a
possible mechanism whereby retinoid signal-
ling was disturbed, so that it might be of
relevance in schizophrenia.74 In contrast, com-
pulsive running was shown to downregulate
striatal NGFI-B and NOR-1 expression.76
Thus, these two transcription factors appear to
be involved in dopaminergic related personality
characteristics. However it is still unclear
whether Nurr 1 has similar properties to
NGFI-B, and whether and how the expression
of NGFI-B and NOR-1 changes and, if it does,
how such changes coincide with any alterations
in the expression of Nurr 1 in idiopathic
Parkinson’s disease. Because of the complex
way that all three principle members of the
NGFI-B family act as individuals and interact
with each other and other liganded nuclear
receptors, such as the retinoid and glucocorti-
coid receptors,77 78 these proteins have the
capacity to modulate the transcription of many
genes, only a few of which have been
recognised, and to act as both survival and
proapoptotic factors, not necessarily by modu-
lating events in the cell nucleus. This complex-
ity is increased by the fact that further proteins
are formed from the same genes by either exon
splicing or the use of diVerent transcription
start sites and promoters.79 These also have
transactivator properties; the Nurr 1 related
protein (TINUR) derived by diVerential splic-
ing is induced in T cells undergoing apopto-
sis.80
The elucidation of the actions of all three
major proteins should give insights into
dopaminergic neuronal cell survival and death
in the substantia nigra, either because the
function of Nurr 1 in these cells has changed or
because the functions of NGFI-B or NOR-1 in
neurones in target sites have changed, causing a
lack of support for the incoming dopaminergic
neurones. In turn, such knowledge may give
insights into the biochemical basis of some of
the behavioural and personality features of the
disease, in addition to the cause of the neuronal
death.
However, zinc finger nuclear receptors are
not the only transcription factors that are of
interest in dopaminergic neurone development
and survival. Two others which are members of
diVerent families are being increasing recog-
nised as important. These are Lmx1b and
Ptx-3. Both are homeobox proteins.
LMX1B AND PENTAXIN 3 (PTX-3)
Although Nurr 1 expression is essential for the
final diVerentiation of stem cells into dopamin-
ergic neurones, it cannot initiate and complete
this process by itself.81 Neuronal development
and diVerentiation occur as a consequence of
the actions of successive waves of transcription
factors. In the early phases of the transforma-
tion of stem cells sonic hedgehog and fibroblast
growth factor 8 (FGF-8) appear to be principal
players.82 83 Another transcription factor that
acts at this early stage is Lmx1b. The
expression of this factor is stimulated by
FGF-8 and, as part of this cascade, Lmx1b in
turn stimulates another transcription factor,
wnt1.84
Lmx1b is a member of the LIM homeodo-
main protein family and was first recognised
because of its role in dorsal–ventral limb
patterning. It is expressed in numerous tissues
where it aVects skeletal, cranial, renal, and eye
structures,85–87 and the trajectory of motor neu-
rones in limbs.88 Subsequent studies have
shown that loss of function mutations in the
human gene are responsible for the nail-patella
syndrome.89–94 Its role in dopaminergic neuro-
nal development is only just beginning to be
elucidated. It is expressed in the neural tube at
an early stage in the genesis of mesencephalic
dopaminergic neurones in response to FGF-8
stimulation, where it maintains the expression
of another transcription factor Wnt1,84 and in
the normal adult midbrain.95 Lmx1b knockout
mice fail to develop the full repertoire of
dopaminergic neurones and their gene prod-
ucts. Although Nurr 1 and tyrosine hydroxylase
are still expressed, there is a failure of
expression of Ptx-3.
Later and at almost the same time as Nurr 1
is expressed, another transcription factor—
Ptx-3—appears (embryonic day 11.5 in the
rat).16 In the CNS, this factor is found only in
mesencephalic dopaminergic neurones, unlike
Nurr 1 and the other factors mentioned above,
but its expression does not by itself lead to the
formation of the final dopaminergic pheno-
type. In Nurr 1 deficient (−/−) mice, Ptx-3 is
expressed normally in the progenitor cells but
these do not survive.37 However, the import-
ance of Ptx-3 for these neurones can be seen by
the fact that a Ptx-3 response element
(GGCTTT) is present in the 5' flanking
regions of the human, rat, and mouse tyrosine
hydroxylase genes, and binding of the tran-
scription factor to this element results in
pronounced upregulation of transcription.30
Ptx-3 expressing neurones are reduced in
number in parkinsonian substantia nigra and in
that of the 6-hydroxydopamine lesioned rat.
However, whether the neuronal loss in these
situations is related to Ptx-3 function, or the
reduction in Ptx-3 is simply a consequence of
the death of these neurones, is uncertain.
Nevertheless, it is principally the Ptx-3 express-
ing neurones that die.94
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Genetic and environmental aetiological
factors
The above discussion has concentrated on
transcription factors that are involved in
dopaminergic neurogenesis and have func-
tions, as yet ill defined, in the adult CNS.
Whether they have a role in the aetiology of
idiopathic Parkinson’s disease is very uncer-
tain, but they clearly have the potential to be
involved in this. By definition, the causes of
idiopathic Parkinson’s disease are as yet
unknown. Over the past two decades, scientific
opinion has varied between two extreme poles:
from there being only environmental causes, to
the position where genetic factors are consid-
ered to be the dominant aetiological feature.
One major stimulus to this refocusing of
emphasis on to genetics has stemmed from the
ability to visualise dopaminergic neurones in
vivo by positron emission tomography (PET)
scanning. Early twin studies, before PET scan-
ning was available, showed no significant
diVerence between the incidence of idiopathic
Parkinson’s disease in the second twin when
monogyzotic and dizygotic pairs were com-
pared. On PET scanning of small groups, sec-
ond monozygotic twins were found to have a
greater dopaminergic deficit than dizygotic
partners, suggesting than genetic parameters
are important.96 A second stimulus is the early
finding that continues to be re-emphasised
with studies of increasing sophistication, in
terms of the elimination of potential confound-
ing factors, is that a considerable proportion of
patients with apparently sporadic idiopathic
Parkinson’s disease have a family history of the
disease.97–99 In addition, advances in molecular
biological techniques, such as whole genome
scanning, reviewed and illustrated in an earlier
edition of this journal, have made the explora-
tion of genetic factors possible.100 This has been
particularly important in elucidating the genes
involved in familial Parkinson’s disease.
In contrast to the twin study quoted above,
other recent major studies not based on PET
scanning have failed to detect a significant dif-
ference between the incidence of idiopathic
Parkinson’s disease in monozygotic compared
with dizygotic twins, leading the authors to the
conclusion that genetic factors are of minor
importance in the aetiology of the disease.101 102
The emphasis on causal environmental agents
received a boost with the recognition of the
selective toxicity of rotenone in mice.103 This is
quite widely used as a “safe” insecticide. The
compound is also a potent inhibitor of
mitochondrial complex 1 and thus shares a
common mode of action with 1-methyl-4-
phenylpyridinium ion (MPP+) formed from in
vivo oxidation of the protoxin, MPTP. The
recognition that a new class of rotenone-like
compounds might exist in the environment
helps to counter one objection to the concept
that environmental toxins might be involved in
the aetiology of idiopathic Parkinson’s disease,
simply that MPTP is not encountered in
nature. Although this is the case for MPTP,
MPP+-like compounds may be, and this possi-
bility is discussed in a later section.
Whether either of these opposing opinions or
a combination of the two is correct remains to
be seen, but because most eVort has been
directed to elucidating the genetic basis of
familial Parkinson’s disease. Consequently,
these developments will be reviewed first.
FAMILIAL GENETIC LOCI
To date, the genetic loci that have been found
to be associated with Parkinson’s disease with
fairly typical symptoms are:
+ A locus on chromosome 4q, which encodes
the protein á synuclein. The mutations
involved are A30P and A53T.104 105
+ A locus on chromosome 6q, which encodes
the protein parkin. Multiple mutations are
involved.106–108
+ A locus on chromosome 4p, which encodes
the protein ubiquitin C-terminal hydrolase
(UCTH). The mutation involved is I93M.109
+ A locus on chromosome 4p, which encodes
an unknown protein.110
+ A locus on chromosome 2p13, which
encodes two unknown proteins,111 112 and
cytochrome b.113
In addition, there are other loci associated
with atypical symptoms. For example, a locus
on chromosome 17q21–22, which encodes the
protein tau and which is associated with
frontotemporal dementia,114–116 and a locus on
chromosome 19q13, which is associated with
rapid onset dystonia Parkinson’s disease.117
There are other loci that are associated with
other modes of inheritance than the autosomal
dominant transmission described in the origi-
nal family with the á synuclein mutation.
These include:
+ Autosomal recessive—several mutations in
the parkin gene.106–108 118
+ Autosomal dominant inheritance because of
parkin gene mutation.119
+ Maternal transmission—mutations in mito-
chondrial DNA.120
Other loci are associated with both unusual
features and mode of transmission—for exam-
ple, a 12S ribosomal RNA gene point mutation
causing disrupted protein synthesis resulting in
parkinsonism, deafness, and neuropathy.121
Despite the increasing number of kindred
being described, familial parkinsonism ac-
counts for a relatively small proportion of the
total patient population; therefore, the reason
for the interest in these cases, apart from that of
knowing the details of the causal mutation in
each, is that they may shed light on the aetiolo-
gies of sporadic cases. This is proving to be the
case to a surprising extent, although the muta-
tions in the familial cases are not found in spo-
radic idiopathic Parkinson’s disease.122–125 (In
fact, it has been suggested that another
relatively common mutation in the UCTH
gene, S18Y, is protective.122) What has been
highlighted from this work is the importance of
two inter-related pathways: á synuclein fibril
formation and ubiquitin targeted protein ca-
tabolism.
á Synuclein is a member of a small family of
proteins (other members being â synuclein and
persyn). Under normal circumstances, it is
strongly expressed in neurones in a limited
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number of areas of the brain, including the
dopaminergic neurones of the substantia nigra
(a feature in common with parkin and in con-
trast to ubiquitin carboxy terminal hydro-
lase126), and comprises about 2% of total brain
protein.127 Its physiological role is ill defined,
but it is present in nerve terminals. Its import-
ance was recognised because of the fact that,
together with proteasome and synphilin-1, and
in whole and partially digested forms, it is a
major component of Lewy bodies, which are a
cardinal feature of the pathology of the parkin-
sonian brain. Of added importance are the
facts that the proteins composing Lewy bodies
are heavily ubiquitinylated and they are resist-
ant to proteolysis.128–132 The mutations discov-
ered in the initial parkinsonian families were
thought either to render á synuclein more
resistant to proteolysis or to have a greater ten-
dency to form fibrils, and in these ways
accelerate Lewy body formation, thereby eVec-
tively clogging up the cytosol of the neurone
and killing it.133
In support of this relatively simple scenario
was the discovery of the mutation in the ubiq-
uitin C-terminal hydroxylase gene. The ubiqui-
tin targeted pathway of intracellular protein
catabolism utilises initially three classes of pro-
teins, corresponding to the three steps in the
first phase of the pathway—ubiquitin activa-
tion, ubiquitin conjugation, and target protein
ligation—to attach the polyubiquitin tail to the
protein to be destroyed. Ubiquitin C-terminal
hydroxylases in the final step release ubiquitin
from this polyubiquitin tail for re-use after
digestion of the target protein by the 26S pro-
teasome complex.134 An inability to release
ubiquitin from the polyubiquitin tail, as a result
of deficient ubiquitin C-terminal hydrolase
activity, with the resultant absent or incomplete
digestion of the target protein, could allow the
accumulation of the building blocks for neuro-
toxic fibrils.
The first diYculty with this simple scenario
in which toxicity occurs because of cytosolic
blockage is the Japanese families with parkin
gene defects. These defects give rise to an early
onset form of Parkinson’s disease. In the few
individuals who underwent necropsy no Lewy
bodies were found. While the function of the
parkin gene product was unknown, this diY-
culty could be explained away, but it is now
clear that the gene gives rise to a ubiquitin
ligase.135 These enzymes are of crucial import-
ance for attaching the initial ubiquitin to the
target protein and then extending the ubiquitin
chain. Lack of Lewy bodies in individuals with
gross genetic mutation that inactivate the
enzyme presumably arises from the fact that
á synuclein and other proteins are not ubiquiti-
nylated, so they do not progress to the point
where partially digested material is available for
fibril formation. Hence, simple cytosol block-
age by insoluble proteins is not the only cause
of cell death, which, therefore, may be caused
by the inability to clear soluble proteins in these
cases.
Second, in most sporadic cases investigated
no mutation in the á synuclein gene has been
found and it is not clear from in vitro
experiments that the variant á synucleins have
a significantly greater rate of fibril formation
when compared with that of the wild-type,
which nevertheless does form fibrils.136 These
facts pose questions of how Lewy body forma-
tion occurs in sporadic Parkinson’s disease and
how this is related to cell death. Factors that
may be more relevant than the rate of fibril for-
mation are interactions with other proteins,
such as synphilin-1137; the rates of formation of
soluble oligomers of á synuclein, a step that
precedes fibril formation,138 139 which aVects
mitochondrial function140; and the nucleation
of fibril formation.141 In the last instance, the
role of iron as the instigator of fibril nucleation
has been suggested to be important.142 In
health, the pigmented dopaminergic neurones
normally have relatively high concentrations of
both iron and copper, and in the clinical phase
of the disease increased amounts of low
molecular weight iron and copper compounds
are released in the cerebrospinal fluid.143 Thus,
the iron released from one dead or dying cell
may be available to propagate fibril nucleation
in other cells.
Third, it is worth repeating that none of the
genetic abnormalities seen in the familial cases
is seen in most of the patients. Therefore, if the
inability to catabolise á synuclein and other
proteins is not only the basis of Lewy body for-
mation but the ultimate reason why the
neurone dies, a defect must exist that precedes
and precipitates this. Such a conclusion is sup-
ported by the existence of the well character-
ised familial cases that result from mito-
chondrial DNA mutations where genomic
DNA mutations can be discounted.120 This
leads back to themes that are familiar to those
in the immediate field: oxidative stress, mito-
chondrial complex 1 underactivity and energy
production, excitotoxicity, and dopamine me-
tabolism. In addition, as pointed out by Gold-
berg and Lansbury, one consequence of events
before fibril formation occurring being of
prime importance may be that a therapeutic
approach directed solely at inhibiting the
polymerisation of protein into fibrils might not
be beneficial.138
ENDOGENOUS GENERATION OF SELECTIVE
NEUROTOXINS
The evidence that the substantia nigra in idio-
pathic Parkinson’s disease experiences free
radical mediated oxidative stress has been
reviewed exhaustively on numerous occa-
sions,144 and the abnormally low mitochondrial
complex 1 activity well documented previ-
ously,145 so neither will be discussed in detail
here. That overexcitation of receptors such as
the á1B-adrenergic receptor might lead to
neurodegenerative disease also continues to
receive support, as in the recent findings in
multiple system atrophy.146 However, in idio-
pathic Parkinson’s disease the things that are
not clear are: (1) whether oxidative stress
precedes complex 1 inhibition or vice versa,
and (2) how excitotoxicity relates to the two.
The MPTP model of idiopathic Parkinson’s
disease would suggest that underactivity of
complex 1 leads to oxidative stress. This
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reduced activity could occur because of the
presence of some inhibitory neurotoxin, or as a
result of the accumulation of random replica-
tion errors in mitochondrial DNA. In terms of
neurotoxins, two classes of compounds have
been investigated extensively: cysteine-
dopamine reaction products and MPP+-like
molecules.
The salient feature of MPP+ is the aromatic
quaternary N-methyl, which allows it to bind to
complex 1 but, because such a charged
molecule would not pass the blood–brain bar-
rier, intra CNS routes of synthesis are required,
as in the case of the conversion of MPTP to
MPP+ by monoamine oxidase B. One such
route is N-methylation, with simple pyridines,
â carbolines, and tetrahydroisoquinolines as
substrates. Members of these classes of com-
pounds are present in the food chain, the gen-
eral environment, and in the human brain and
cerebrospinal fluid.147 Enzymes that can con-
vert them into their N-methylpyridinium ana-
logues are also present in the mammalian
brain.148 In an apparently analogous fashion to
MPP+, the N-methyl derivatives are selectively
neurotoxic, interact with the dopamine uptake
system, and inhibit mitochondrial respiration.
In the case of â carbolines, the molecule can be
N-methylated at two sites, and the kinetics of
the two reactions are diVerent. However, the
enzyme(s) responsible has not been isolated
and cloned, so it is not clear whether the two
activities observed represent diVerent actions
of the same enzyme or two entirely diVerent
ones. Following on from earlier work by
Matsubara et al,147 who showed that â carboline
concentrations in the cerebrospinal fluid of
patients with Parkinson’s disease were higher
than those of control subjects, Gearhart et al
have shown increased â carboline 9N-
methyltransferase activity in the frontal cortex
of parkinsonian brain compared with that of
non-parkinsonian brain.149 Thus, there appears
to be both higher amounts of substrate and one
form of enzyme activity in the disease popula-
tion.
Our own work in this area has concentrated
on nicotinamide-N-methyltransferase
(NNMT), which, apart from catabolising the
amide form of vitamin B3, has a wide substrate
specificity that enables it to generate a variety
of potentially toxic N-methylpyridinium ions.
Its expression is dominated by an as yet unde-
termined, non-coding, genetic polymorphism,
which results in a quarter of the general popu-
lation having high hepatic enzymic protein and
activity values.150 Because nicotinamide is an
integral part of NADH, which is the electron
and hydrogen donor for complex 1, catabolism
of nicotinamide could conceivably have an
eVect on intracellular NADH values. Thus,
NNMT links, albeit tenuously, the ability to
produce N-methylpyridinium ions, the me-
tabolism of NADH, complex 1 activity, and the
genetics of 25% of the general population. In
exploring the hypothesis that NNMT may be
an aetiological factor in idiopathic Parkinson’s
disease, some of our initial findings are that the
enzyme is expressed in neurones and in higher
amounts in two regions of the brain (caudate
nucleus and cerebellum) in Parkinson’s disease
compared with control brain (cerebellum, fig
1). The enzyme is expressed in the substantia
nigra,151 but the destruction of so many
neurones that has occurred in this area by the
time subjects reach necropsy makes compari-
sons between parkinsonian and non-
parkinsonian material diYcult to interpret.
Figure 1 Expression of nicotinamide-N-methyltransferase (NNMT) protein and mRNA in control (non-Parkinsonian)
and Parkinsonian cerebellum. (A) Protein expression in non-Parkinsonian cerebellum. Counterstain only (blue) is present.
(B) Protein expression in the Parkinsonian cerebellum. Brown staining indicating the presence of NNMT protein is present
solely in the neurones of the granular layer, with little or no staining in the white matter and the molecular layer. (C)
mRNA expression in the non-Parkinsonian cerebellum. Little expression indicated by blue/purple staining was present in the
granular layer. (D) mRNA expression in the Parkinsonian cerebellum. Pronounced blue/purple staining indicating the
presence of NNMT mRNA is present solely in the granular layer, with no staining in either the white matter or the
molecular layer.
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How NNMT relates to â carboline
N-methyltransferases and tetrathydroisoquino-
line N-methyltrnasferase is unclear, but as
Gearhart et al pointed out, these may all be the
same entity.149 If so, the collective evidence
from the three areas would present a strong
case for N-methylpyridinium ion formation
being an important aetiological factor.
A second area of biochemistry where the
generation of neurotoxins has been explored is
that of dopamine metabolism. The arguments
as to whether dopamine itself is deleterious to
the neurone when considered in relation to
L-DOPA treatment have been well rehearsed
previously and will not be repeated here. One
aspect of endogenous dopamine metabolism
that has not received wide attention is that of its
interaction with cysteine. Work in this area has
been carried out in the main by the group led
by Dryhurst. This group has shown that under
mild oxidising conditions cysteine and
dopamine or other catecholamines react to-
gether to form a variety of compounds, includ-
ing dihydrobenzothiazines, which are potent
inhibitors of complex 1, and free radical
species.152–158 If the products of these reactions
are involved in the aetiology of the disease,
because the neurone has evolved to generate
dopamine, factors that control the intracellular
concentration of the other reactant (cysteine)
would be important. Within the hepatocyte,
the enzyme cysteine dioxygenase is one such
factor. Therefore, we explored the possibility
that this enzyme, which has been shown to be
expressed in brain previously,159 is expressed in
dopaminergic neurones. To date, we have
shown that, in the rat, the enzyme is present in
numerous brain regions and the highest
unstimulated activity can be seen in the basal
ganglia and olfactory bulb.160 Inspection of
chromosome 5 sequence data in GenBank
shows a potential Ptx-3 response element
within 2 kb of the transcription start site of the
gene, suggesting that this exclusively dopamin-
ergic transcription factor may be involved in
the regulation of expression. Initial immuno-
histochemistry shows that the enzyme is
present in neurones,161 and further work is
under way to characterise expression in the
human substantia nigra. Relatively little work
has been done on the genetics of cysteine
dioxygenase regulation, but some phenotyping
studies suggest that most of the population has
a low to medium degree of constitutive activity,
with a small proportion being in a high activity
group.162 A low activity would favour a high
intracellular cysteine concentration and hence
the formation of toxic reaction products.
THE GENETICS OF “NON-FAMILIAL” PARKINSON’S
DISEASE: CANDIDATE GENES
The work outlined in the previous section may
be categorised as a “candidate toxin” approach
to elucidate the aetiology of idiopathic Parkin-
son’s disease. However, the general emphasis
on genetics has led to other themes such as
xenobiotic metabolism and links with
Alzheimer’s disease. Polymorphic alleles are
sought that are more or less common in the
idiopathic Parkinson’s disease population com-
pared with the control population, controls
being either age and sex matched to varying
extents, or sibling pairs. Many genes have been
investigated and a few phenotypic studies
carried out. Examples of genes investigated in
some recent studies are CYP1A1,163 the
dopamine D2 receptor gene,164 tau,165 and
apolipoprotein E.166 In addition, associations
between Parkinson’s disease and combinations
of genetic loci, such as á synuclein and apo
lipoprotein E alleles167 have been investigated.
On the whole, the results of such studies have
been unconvincing. One group will present
evidence of an allele being positively associated
with the development of idiopathic Parkinson’s
disease, only for another group either to fail to
find the correlation with the disease or to give
another interpretation. An example of this is
the case of the NAT2 alleles, where Bandmann
and colleagues168 169 claim a positive association
between the “slow acetylator” genotype and
the development of idiopathic Parkinson’s dis-
ease in what they call a “familial” Parkinson’s
disease group—a group composed of individu-
als with at least one aVected relative—as
opposed to the classic, “large family” studies,
which identified the mutant á synuclein and
parkin genes referred to earlier. This was
suggested in a smaller scale phenotypic study
too.170 In contrast, Harhangi et al had failed to
find this connection in randomly selected
patients with idiopathic Parkinson’s disease
and claim that the genotype is a marker of
mortality in the general population.171 We also
failed to find this connection,163 although
patient selection was not identical to that of
Bandmann et al.
The question arises, therefore, of how to
interpret the results of such studies. Where two
or more groups have put forward opposing
findings, has one side simply got it wrong? If so,
how does one tell which? In the case of
CYP2D6 alleles, which were suggested to be
important by both separate, early phenotyp-
ing172 and genotyping173 results, the weight of
evidence from repeat studies by other groups
has tipped the scales against these
conclusions.163 174–176 Nevertheless, it would be
depressing to think that such a process would
have to be gone through for every candidate
gene that is dreamt up. It may be argued that
whole genome scanning will obviate this prob-
lem. However, in the case where it has been
most successful in identifying susceptibility loci
in a common multigene disease—diabetes
mellitus, type 1—the genetic link in families is
stronger than in idiopathic Parkinson’s disease,
much larger population groups and family
clusters were studied, and controls were
carefully matched. Thus, if one accepts the
multigene hypothesis, it presents huge logisti-
cal problems in terms of sample acquisition
and classification to achieve adequate statistical
power to recognise small diVerences in allelic
frequencies. Moreover, the case for a geneti-
cally based aetiology is still strongly chal-
lenged,100 and although the multigene hypoth-
esis may form a convenient way of explaining a
baZing problem, it is not necessarily correct.
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In an essential monogenic disease such as
familial amyloidotic polyneuropathy a single
mutation in a single gene can give rise to greatly
diVerent phenotypic forms of expression. In
the case of the Met30 variant transthyretin, the
Portugese expression is one of lower limb
involvement and renal failure,177 whereas in a
Danish family the heart is the organ primarily
aVected.178 Presumably, this arises in part from
the interaction of diVerent levels of gene prod-
ucts in the two populations. A similar scenario
(in this case a combination of apolipoprotein E
and á synuclein alleles179), compounded by the
eVects of exposure to varieties of natural (such
as homocysteine180) and man made toxicants
(such as lead181), might also explain the multi-
farious features of the entity we call idiopathic
Parkinson’s disease.
Conclusions
We are some way from unravelling the conun-
drum of the aetiology of idiopathic Parkinson’s
disease, although two big advances have been
made. The first is the elucidation of the genetic
defects in large aVected kindreds, which has
pointed to the importance of defects in ubiqui-
tin targeted á synuclein catabolism for Lewy
body formation, and as a likely end reason for
death of the dopaminergic neurone in idio-
pathic Parkinson’s disease. However, the initial
precipitating problem is uncertain. Whether it
is falling ATP concentrations, the accumulative
eVects of the inadequate clearance of oxidative
free radicals, overexcitation of the neurone, or
low amounts of neurotrophic support remains
to be resolved.
The second major advance is the increasing
recognition of the factors involved in dopamin-
ergic neurogenesis, which, in addition to the
intrinsic importance of the knowledge, will
allow the application of these factors to
produce good model in vitro culture systems.
Hopefully, such in vitro cultures, coupled with
hybrid systems, which were first described a
decade ago and that are beginning to elucidate
mitochondrial defects,182 183 will provide the
tools that are needed to enable the conundrum
to be explained.
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